Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May;5(1):11-25.
doi: 10.2217/ijh-2016-0002. Epub 2016 May 5.

Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia

Xavier Thomas  1 , Caroline Le Jeune  1
Affiliations
Review

Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia

Xavier Thomas et al. Int J Hematol Oncol. 2016 May.

Abstract

l-asparaginase, an enzyme originally derived from Escherichia coli, represents a major drug in the treatment of acute lymphoblastic leukemia. However, the occurrence of major adverse effects often leads to early withdrawal of the enzyme. Main side effects include immune-allergic reactions, coagulopathy, pancreatitis and hepatic disorders. Novel asparaginase formulations and alternative sources have been developed to address this issue, but the results were not totally satisfactory. l-asparaginase loaded red blood cells (RBCs; GRASPA) represent a new asparaginase presentation with reduced immunological adverse reactions. RBCs protect l-asparaginase, enhance its half-life and reduce the occurrence of adverse events. We reviewed the history, biology and clinical experiences with l-asparaginase, and the characteristics and first clinical experiences with GRASPA in the treatment of acute leukemia.

Keywords: -asparaginase; acute leukemia; chemotherapy; erythrocyte encapsuled -asparaginase; safety profile; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure X Thomas received honoraria for advisory boards from Erytech. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. l-asparaginase converts plasmatic l-asparagine into l-aspartate plus ammonia.
Leukemia cells are deficient in asparagine synthetase. l-asparagine deprivation, due tol-asparaginase activity, leads to asparagine starvation impairing protein biosynthesis in leukemia cells and then leading to apoptosis through cellular dysfunction.
<b>Figure 2.</b>
Figure 2.. Mechanism of action of GRASPA.
<b>Figure 3.</b>
Figure 3.. Schema of the GRASPALL 2009-06 Phase 2/3 randomized trial testing GRASPA versus native l-asparaginase in combination with standard polychemotherapy (COOPRALL regimen) in patients with first recurrence of Ph chromosome-negative acute lymphoblastic leukemia in adults and children with or without known hypersensitivity to l-asparaginase.
Patients with no prior history of allergy were randomized between GRASPA (150 IU/kg) and native l-asparaginase (10,000 IU/m2), while patients with a prior history of allergy received systematically GRASPA. †GRASPA-S: Single cohort in allergic patients. 6-MP: 6-mercaptopurine; ALL: Acute lymphoblastic leukemia; ASP: Asparaginase; mo: Month; MTX: Methotrexate; PS: Performance status.
<b>Figure 4.</b>
Figure 4.. The GRASPA-AML 2012-01 study schedule.
Randomization was 2:1 with a combination of low-dose cytarabine (40 mg daily per day from day 1 to day 10) with GRASPA (100 IU/kg on day 11) in the experimental arm, and LDC (40 mg daily per day from day 1 to day 10) alone in the control arm. AML: Acute myeloid leukemia; C: Cycle; LDC: Low-dose cytarabine; RANDO: Randomization.
See this image and copyright information in PMC

References

    1. Kidd JG. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Courses of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum or rabbit serum. J. Exp. Med. 1953;95:565–582. - PMC - PubMed
    1. Broome JD. Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature. 1961;191:1114–1115. - PMC - PubMed
    1. Yellin TO, Wriston JC., Jr Antagonism of purified asparaginase from guinea pig serum toward lymphoma. Science. 1966;151:998–999. - PubMed
    1. Mashburn LT, Wriston JC. Tumor inhibitory effect of L-asparaginase from Escherichia coli . Arch. Biochem. 1964;105:451–452. - PubMed
    1. Old LJ, Boyse EA, Campbell HA. L-asparagine and leukemia. Sci. Am. 1968;219:34–40. - PubMed

LinkOut - more resources